It is a link to move in the page.
- Font Size
-
- Language
TOP
News Release Back number
2012
- January 18, 2012
- Bonalon Bag for I.V. Infusion 900 µg Approved as Japan’s First I.V. Drug for Osteoporosis
2011
- July 28, 2011
- Febuxostat (FEBURIC®) Launches in Korea - Novel Drug for Treatment of Chronic Hyperuricemia in Gout Patients -
- May 13, 2011
- Teijin Pharma to Launch Feburic® (febuxostat) in Japan — First Drug for Chronic Management of Hyperuricemia in 40 Years—
- April 18, 2011
- Teijin Pharma Expands Global Market for TMX-67 (febuxostat) Turkey, Mexico, Caribbean, Middle East and North Africa
- April 6, 2011
- Teijin Pharma Launches Alvesco® 100μg Inhaler 56 Puff in Japan - Inhaled Steroid for Bronchial Asthma for Pediatric Use Now Available -
- March 14, 2011
- Teijin Group's Status After Tohoku–Pacific Offshore Earthquake
- March 14, 2011
- Teijin Supports Japan Earthquake Disaster Relief Efforts
- January 21, 2011
- TMX-67 (febuxostat) Approved in Japan Teijin-developed Novel Drug for Chronic Management of Hyperuricemia
- January 21, 2011
- Alvesco® Inhaled Steroid for Bronchial Asthma Approved for Pediatric Use in Japan
2010
- October 27, 2010
- TMX-67 (ULORIC®) Launches in Canada — Novel Drug for Chronic Management of Hyperuricemia in Gout Patients —
- April 1, 2010
- Teijin Pharma and Astellas Pharma Enter into Agreement for Marketing Rights of TMX-67 in China and Hong Kong — Novel Drug for Chronic Management of Hyperuricemia in Gout Patients —
- March 11, 2010
- Teijin Pharma Strengthens Presence in Spain’s Home Healthcare Field Furthers Business Expansion in European Market
- March 9, 2010
- TMX-67 (ADENURIC®) Launches in Europe Novel Drug for Chronic Management of Hyperuricemia in Gout Patients
2009
- December 25, 2009
- Teijin Pharma Submits New Drug Application for TMX-67, Chronic Management of Hyperuricemia in Patients with Gout in Japan
- October 20, 2009
- Exclusive European Sublicensing Agreement Signed for Teijin-developed TMX-67 Gout Treatment
- June 30, 2009
- Marketing Authorization Granted by KFDA for TMX-67, Chronic Management of Hyperuricemia in Patients with Gout
- May 12, 2009
- Teijin Pharma Licenses Marketing Rights of TMX-67 in Taiwan to Astellas Pharma Taiwan for Treatment of Hyperuricemia in Patients with Gout
- March 13, 2009
- Click on the link to go to Takeda Pharmaceuticals English Web page: ULORIC® (febuxostat) 40-mg and 80-mg Tablets Now Availablefor the Chronic Management of Hyperuricemia in Patients with Gout
- March 5, 2009
- Nissan Chemical Industries and Teijin Pharma License Ex-Japan Rights for Atrial Fibrillation/Flutter Drug to Bristol-Myers Squibb
- February 14, 2009
- ULORIC® (TMX-67, febuxostat) Receives FDA Approval for the Chronic Management of Hyperuricemia in Patients with Gout
- January 19, 2009
- Review of Febuxostat New Drug Application to Continue after PDUFA Date
2008
- December 19, 2008
- Teijin Pharma to Launch Home Healthcare Business in Europe
- May 30, 2008
- Teijin to Acquire Leading Home-use Medical Equipment Provider in U.S.
- May 7, 2008
- Marketing Authorization granted by European Commission for Adenuric® (TMX-67, febuxostat) for the treatment of hyperuricaemia in gout
- April 1, 2008
- TEIJIN PHARMA LIMITED SIGNS AGREEMENT FOR NOVEL OSTEOPOROSIS TREATMENT
- February 25, 2008
- Positive Opinion from European Regulatory Authorities for TMX-67 (febuxostat) for the treatment of hyperuricaemia in gout
2007
- August 23, 2007
- Teijin and Chugai enter an agreement to co-develop Ipsen's anti-diabetic medicine in Japan
- June 8, 2007
- Launch of Alvesco®, Ethical Drug for the Treatment of Asthma
- April 18, 2007
- Teijin Announces Manufacturing and Marketing Approval in Japan for "Alvesco®"
2006
- September 15, 2006
- Launch of Bonalon® Tablet 35 mg, Ethical Drug for the Treatment of Osteoporosis
- July 26, 2006
- Manufacturing and Marketing Approval for Bonalon® Tablet 35 mg, Ethical Drug for the Treatment of Osteoporosis
2005
2004
- August 6, 2004
- Distributorship Agreement for New Anti-gout and hyperuricemia in South Korea
- July 1, 2004
- A sales agreement with Grelan Pharmaceutical (Japanese partner of Fournier Pharma, France) enabling Teijin Pharma to be an additional partner in Japan for promotion of novel co-micronized formulation of fenofibrate
